

## IMPORTANT CLINICAL LABORATORY MEMORANDUM

Date: 4/26/2022

To: CAMC Providers  
CAMC Staff  
CAMC LabWorks Clients

From: Milton Plata, MD  
Laboratory Director – CAMC Laboratory

**TOPIC:** Leukocyte Alkaline Phosphatase (LAP) Testing

**EFFECTIVE:** April 26, 2022

Starting **April 26<sup>th</sup>, 2022**, **CAMC Laboratories** will be removing Leukocyte Alkaline Phosphatase (LAP) Testing from the testing menu. With the advancement of molecular testing, a blood smear LAP score to distinguish chronic myelogenous leukemia (CML) from other myeloproliferative neoplasms and benign etiologies provides no real clinical or diagnostic value.

- If CML is a consideration, ordering BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay on peripheral blood would be appropriate.
- If polycythemia vera (PV) or other myeloproliferative neoplasms are part of the differential diagnosis, ordering JAK2 V617F Mutation Detection (with reflex testing to CALR and MPL Mutations if necessary), blood would be appropriate.

If you have any concerns or questions, feel free to contact **Dr. Oscar Estalilla at 304-388-4268**, **Dr. Stephanie Wright at 304-388-4124** or **Shawn Farren (Special Hematology) at 304-388-4332** Thank you!